Please login to the form below

Not currently logged in
Email:
Password:

Akzo Nobel

This page shows the latest Akzo Nobel news and features for those working in and with pharma, biotech and healthcare.

Pharma news in brief

Akzo to spin off pharma unit. Dutch chemicals and drug group, Akzo Nobel has announced it plans to spin off its pharmaceutical business after full year net profits for 2005 rose ... said Akzo chief executive Hans Wijers.

Latest news

  • EMEA seeks SSRI warning

    Other medicines covered by the EMEA review included other Lilly products Cymbalta and Strattera, Lundbeck's Celexa and Lexapro, Pfizer's Zoloft, Wyeth's Effexor and Akzo Nobel's Remeron.

  • Xceleron and Organon sign microdose study agreement

    UK-based contract research organisation Xceleron has revealed a collaboration with Organon, the human healthcare business unit of Netherlands-based Akzo Nobel, on a three-compound human microdose study focusing on

  • Schering-Plough completes Organon BioSciences acquisition

    The US company paid approximately EUR 11bn in cash for the company, which used to be a subsidiary of Dutch chemicals giant, Akzo Nobel.

  • Schering-Plough sales double on statins

    Organon acquisition. S-P is in the middle of acquiring Akzo Nobel's Organon unit, which is the second-largest EU manufacturer of contraceptive pills, in order to diversify away from ... In March 2007, S-P announced it was going to purchase Akzo Nobel's

  • Organon and MRC sign up for antibody development programme

    The pharmaceutical unit of Dutch chemicals giant Akzo Nobel, Organon, has signed a collaborative agreement with MRC Technology in the UK to develop a humanised antibody for the treatment of certain

More from news
Approximately 0 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics